Published in

Oxford University Press, Brain, 12(146), p. 4880-4890, 2023

DOI: 10.1093/brain/awad328

Links

Tools

Export citation

Search in Google Scholar

Genetic landscape of congenital insensitivity to pain and hereditary sensory and autonomic neuropathies

Journal article published in 2023 by Annette Lischka ORCID, Katja Eggermann, Christopher J. Record ORCID, Maike F. Dohrn ORCID, Petra Laššuthová, Florian Kraft ORCID, Matthias Begemann, Daniela Dey, Thomas Eggermann ORCID, Danique Beijer ORCID, Jana Šoukalová, Matilde Laura, Alexander M. Rossor, Radim Mazanec, Jonas Van Lent and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Congenital insensitivity to pain (CIP) and hereditary sensory and autonomic neuropathies (HSAN) are clinically and genetically heterogeneous disorders exclusively or predominantly affecting the sensory and autonomic neurons. Due to the rarity of the diseases and findings based mainly on single case reports or small case series, knowledge about these disorders is limited. Here, we describe the molecular workup of a large international cohort of CIP/HSAN patients including patients from normally under-represented countries. We identify 80 previously unreported pathogenic or likely pathogenic variants in a total of 73 families in the >20 known CIP/HSAN-associated genes. The data expand the spectrum of disease-relevant alterations in CIP/HSAN, including novel variants in previously rarely recognized entities such as ATL3-, FLVCR1- and NGF-associated neuropathies and previously under-recognized mutation types such as larger deletions. In silico predictions, heterologous expression studies, segregation analyses and metabolic tests helped to overcome limitations of current variant classification schemes that often fail to categorize a variant as disease-related or benign. The study sheds light on the genetic causes and disease-relevant changes within individual genes in CIP/HSAN. This is becoming increasingly important with emerging clinical trials investigating subtype or gene-specific treatment strategies.